The National Post reports in its Tuesday, Feb. 11, edition that two new studies led by Ottawa researcher Dr. Daniel Myran link higher rates of death as well as "concerning increases" in new schizophrenia diagnoses to cannabis use disorder. A Postmedia dispatch to the Post reports that one study found that cases of schizophrenia associated with cannabis use disorder almost tripled in Ontario between 2006 and 2022, a period in which people seeking hospital treatment for cannabis use disorder increased by 270 per cent. The second study found that people who had been treated at hospitals for cannabis use disorder were at a significantly higher risk of death compared with the general population. Both studies, published this past week in the journal JAMA Network Open, are based on data from Ontario over a period that includes cannabis legalization. Canada, the second country to legalize cannabis (in 2018) and the only country to have built a retail market, has some of the best data for research in the area, Dr. Myran said. The recent research suggests the Canadian experience includes concerning health effects.